Regulation Of ICAM-1 Expression In Human Retinal Endothelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$565,967.00
Summary
Posterior uveitis is an inflammation that occurs within the eye and may result in blindness. Present treatments are not directed specifically at the inflamed tissues, and they may be ineffective and cause toxicity. This research aims to identify molecules controlling the entry into the eye from the bloodstream of the white blood cells that cause the disease. The results should suggest new targets for safer drugs to treat patients with posterior uveitis.
Anti-vascular Endothelial Growth Factor-B As A Biologic For Treating Eye Disease
Funder
National Health and Medical Research Council
Funding Amount
$464,295.00
Summary
We plan to show that an engineered antibody fragment against vascular endothelial growth factor-B is an effective therapeutic drug for two eye diseases, corneal neovascularization and age-related macular degeneration. The innovative aspects of this approach are that it may be safer, and have a different spectrum of activity, than existing ophthalmic anti-angiogenic agents. Furthermore, it may be effective for corneal disease when administered as an eye-drop.
A Non-cytotoxic Approach To Reduce Ocular Fibrosis Following Surgery In Glaucoma
Funder
National Health and Medical Research Council
Funding Amount
$586,979.00
Summary
Glaucoma surgery often leads to scar formation and blindness. We have identified a novel protein (NADPH oxidase 4; Nox4) which promotes scar formation in the eye. Lack of Nox4 in a mouse models reduces scar formation. We have demonstrated that a ‘repurposed’ drug which is currently used to treat lung diseases can also block Nox4 in the eye. We aim to determine whether this drug can be used as a novel therapy for vision loss after glaucoma surgery.